Appleton Partners Inc. MA grew its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 14.6% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 58,856 shares of the conglomerate's stock after acquiring an additional 7,492 shares during the quarter. Appleton Partners Inc. MA's holdings in Danaher were worth $12,066,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Fortis Capital Advisors LLC boosted its stake in shares of Danaher by 1.3% during the fourth quarter. Fortis Capital Advisors LLC now owns 3,983 shares of the conglomerate's stock valued at $914,000 after purchasing an additional 50 shares during the period. Fayez Sarofim & Co increased its position in shares of Danaher by 0.6% in the fourth quarter. Fayez Sarofim & Co now owns 8,287 shares of the conglomerate's stock valued at $1,902,000 after acquiring an additional 50 shares during the period. Coastal Bridge Advisors LLC boosted its holdings in shares of Danaher by 4.8% during the fourth quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock worth $252,000 after purchasing an additional 50 shares during the period. Perennial Investment Advisors LLC grew its stake in shares of Danaher by 2.2% in the fourth quarter. Perennial Investment Advisors LLC now owns 2,343 shares of the conglomerate's stock worth $538,000 after purchasing an additional 51 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC increased its holdings in Danaher by 3.1% during the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,739 shares of the conglomerate's stock valued at $399,000 after purchasing an additional 52 shares during the period. Hedge funds and other institutional investors own 79.05% of the company's stock.
Insider Transactions at Danaher
In other Danaher news, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the sale, the executive vice president now directly owns 15,179 shares in the company, valued at $3,005,442. This represents a 51.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the firm's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman now directly owns 3,105,808 shares of the company's stock, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.20% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have recently weighed in on DHR shares. Stifel Nicolaus upgraded Danaher from a "hold" rating to a "buy" rating and set a $260.00 price objective on the stock in a research report on Friday, March 14th. Wolfe Research cut their price target on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a report on Monday, April 7th. HSBC decreased their price objective on shares of Danaher from $270.00 to $240.00 in a report on Friday, April 25th. Wells Fargo & Company reduced their price target on shares of Danaher from $240.00 to $210.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 23rd. Finally, Barclays raised their price objective on shares of Danaher from $215.00 to $225.00 and gave the stock an "overweight" rating in a report on Tuesday. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat.com, Danaher presently has a consensus rating of "Moderate Buy" and a consensus price target of $248.61.
Check Out Our Latest Stock Analysis on DHR
Danaher Price Performance
Shares of DHR stock traded up $1.17 during mid-day trading on Tuesday, hitting $197.51. The company had a trading volume of 2,739,757 shares, compared to its average volume of 3,475,508. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. The stock's 50 day moving average price is $193.96 and its 200-day moving average price is $209.14. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $281.70. The company has a market capitalization of $141.35 billion, a P/E ratio of 38.35, a P/E/G ratio of 2.76 and a beta of 0.77.
Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. The business had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.58 billion. Danaher had a net margin of 15.81% and a return on equity of 10.80%. Equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.
Danaher Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.65%. Danaher's payout ratio is 24.85%.
About Danaher
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
